ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

KALV KalVista Pharmaceuticals Inc

12.07
0.06 (0.50%)
May 16 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 306,594
Bid Price 12.05
Ask Price 13.52
News -
Day High 12.27

Low
7.21

52 Week Range

High
16.88

Day Low 11.7601
Company Name Stock Ticker Symbol Market Type
KalVista Pharmaceuticals Inc KALV NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.06 0.50% 12.07 16:25:00
Open Price Low Price High Price Close Price Prev Close
11.96 11.7601 12.27 12.07 12.01
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,057 306,594 $ 11.98 $ 3,673,169 - 7.21 - 16.88
Last Trade Time Type Quantity Stock Price Currency
19:50:29 3 $ 12.05 USD

KalVista Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
509.21M 42.19M - 0 -92.91M -2.20 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

KalVista Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No KALV Message Board. Create One! See More Posts on KALV Message Board See More Message Board Posts

Historical KALV Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week12.0012.9211.760112.14212,4060.070.58%
1 Month11.5312.9210.1311.60281,5110.544.68%
3 Months13.1114.8010.1312.39517,967-1.04-7.93%
6 Months7.7316.887.3912.85579,2264.3456.14%
1 Year10.0816.887.2111.90407,2981.9919.74%
3 Years26.2030.704.1211.83314,686-14.13-53.93%
5 Years24.0045.004.1216.38288,311-11.93-49.71%

KalVista Pharmaceuticals Description

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.